Vigil Immunotherapy and PARP 7 Treatments for Patients with Ovarian Cancer
Vigil immunotherapy is possible for women with recurrent ovarian cancer and PARP 7 may impact ovarian cancer survival, according to two studies presented in New Orleans.
Vigil immunotherapy is possible for women with recurrent ovarian cancer and PARP 7 may impact ovarian cancer survival, according to two studies presented in New Orleans.
Researchers assessed the use of dupilumab in adults with chronic rhinosinusitis and nasal polyps who did not respond to treatment with intranasal corticosteroids.
The addition of HIPEC resulted in longer recurrence-free and overall survival among patients with ovarian cancer.
Hydrocortisone treatment does not effectively reduce mortality in sepsis.
Bimodal auditory-somatosensory treatment is noninvasive and showed no side effects.
New FDA-approved prophylactic treatment decreases bleeding episodes hemophilia A patients with factor VIII inhibitors.